Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Leadership Change at Nestle Skin Health

By Drug Discovery Trends Editor | October 13, 2016

Humberto Antunes, Nestlé Skin Health CEO, has decided to give a new direction to his career and will leave Nestlé at the end of October 2016. Humberto Antunes joined Galderma in 1997, took over the leadership of Galderma’s worldwide operations in 2004 and finally became Nestlé Skin Health CEO in 2014. During this period the company became a global player in dermatology. Nestlé thanks Humberto Antunes for his contribution and wishes him every success in his new activities.

Paul Navarre is joining Nestlé and will take over from Humberto Antunes as Nestlé Skin HealthCEO on 1 November 2016. Paul Navarre is a French national with an MBA from the ISC Paris Business School who started his career with Procter & Gamble where he spent 15 years in different countries and positions involving both consumer goods and healthcare. He then joined Allergan, a global pharmaceutical company, in 2007 where, after various leadership roles over a period of 10 years, he most recently was President of Allergan International.

Paul Navarre’s consumer goods and healthcare background, his extensive international career and proven leadership skills make him ideally suited to take Nestlé Skin Health to the next level by further pursuing its strategy covering consumer solutions and self-medication, prescription as well as aesthetic and corrective products.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50